OrthoPediatrics Corp. announced on November 13, 2025 that it has added two new pediatric hip bracing systems – the PediHip™ Rigid Brace and the PediHip™ Modular Abduction System – to its Specialty Bracing (OPSB) line. The braces are designed for the treatment of developmental dysplasia of the hip (DDH) and for post‑operative stabilization in children three years old and younger.
The launch brings the OPSB portfolio to 31 distinct systems, creating a seamless hip‑care continuum that spans from early‑stage DDH management to post‑operative support. It also complements the 3P Hip System, which the company introduced in August 2025, reinforcing OrthoPediatrics’ claim as the sole global medical‑device company dedicated exclusively to pediatric orthopedics.
Global market data show the pediatric orthopedics device segment was valued at roughly $4.15 billion in 2024 and $4.87 billion in 2025, with projections ranging from $5.13 billion to $7.78 billion by 2030. OrthoPediatrics aims to capture a larger share of this underserved market by offering anatomically appropriate, high‑quality solutions.
Financially, the company reported Q3 2025 revenue of $61.2 million, up 12% year‑over‑year from $54.6 million in Q3 2024. Q4 2024 revenue was $52.7 million, a 40% jump from the prior year, and full‑year 2024 revenue reached $204.7 million, a 38% increase from 2023. Despite revenue growth, the company posted a net loss of $16.1 million in Q4 2024 and a GAAP diluted EPS of –$0.50 in Q3 2025, with a non‑GAAP EPS of –$0.24. Adjusted EBITDA rose to $6.2 million in Q3 2025, up 56% YoY.
Gross profit margin improved to 74% in Q3 2025 from 73% in the prior year, driven by a favorable product mix that shifted toward higher‑margin specialty braces. Operating margin data were not disclosed, but the margin expansion suggests effective cost control amid growing sales.
Management revised its full‑year 2025 revenue guidance to $233.5 million–$234.5 million, a decrease from earlier guidance. The adjustment reflects headwinds such as delayed 7D capital sales and challenges in Latin and South America, but the company remains confident in maintaining profitability through disciplined cost management.
President Joe Hauser emphasized that the PediHip portfolio demonstrates the company’s commitment to partnering with providers to advance care for children, while CEO David Bailey highlighted 2024 results and the firm’s focus on equipping pediatric orthopedic surgeons with comprehensive technology.
The product launch strengthens OrthoPediatrics’ competitive moat and positions it to capture a larger share of the pediatric hip‑care market. However, the company continues to post net losses and negative free cash flow, with a break‑even target for 2026. Investors should weigh the strategic benefits of the new braces against the ongoing financial challenges and the competitive landscape.
Overall, the expansion signals a focused effort to dominate the pediatric hip‑care continuum, but the company’s financial trajectory and guidance revisions underscore the need for continued execution and cost discipline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.